This RF Safe article argues that the “strongest” RF-EMF literature supports concern about cancer-related findings, emphasizing non-monotonic dose–response patterns in the U.S. National Toxicology Program (NTP) rat study and citing additional analyses and animal studies. It reports that FDA evaluations have downplayed the human relevance of NTP results due to high exposures and inconsistencies, and counters that some effects may occur at lower exposure levels than commonly claimed. The piece also references the Ramazzini Institute rat study as supportive evidence at lower whole-body SARs and mentions a 2024 PLOS ONE paper analyzing Ramazzini tumors, but provides limited detail in the excerpt.